热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
Brilliant Violet 421™ anti-mouse Ly-6G Antib
产品名称：
Brilliant Violet 421™ anti-mouse Ly-6G Antib
产品类别：
抗体
产品编号：
127627
产品应用：
127627
[价格]
规格 价格 库存
125µL ￥ 2052 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Ly-6G transfected EL-4J cell line.
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
Concentration
?g sizes: 0.2 mg/mL
?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Verified
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the ?g size, the suggested use of this reagent is ≤0.5 ?g per million cells in 100 ?l volume. For immunofluorescent staining using the ?l size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

While 1A8 recognizes only Ly-6G, clone RB6-8C5 recognizes both Ly-6G and Ly-6C. Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C15. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A815. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.416.

Additional reported applications (for the relevant formats) include: immunohistochemistry9 of frozen sections10 and paraffin-embedded sections11, depletion4, 12-14, and spatial biology (IBEX)20,21. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for in vivo?studies or highly sensitive assays (Cat. No.?127632, 127649, 127650, 127661 and 127662).

Application References

(PubMed link indicates BioLegend citation)
  1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC)
  2. Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC)
  3. Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC)
  4. Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed
  5. Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed
  6. Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed
  7. Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed
  8. Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed
  9. Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC)
  10. Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC)
  11. Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC)
  12. Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete)
  13. Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete)
  14. Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete)
  15. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  16. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed
  17. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  18. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed
  19. Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed
  20. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  21. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed
  2. Wilden A, et al. 2022. Front Immunol. 13:991295. PubMed
  3. Jong RM, et al. 2022. J Immunol. 208:407. PubMed
  4. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  5. Minutti CM, et al. 2019. Immunity. 50:645. PubMed
  6. Mansouri N, et al. 2019. JCI Insight. 4:e128060. PubMed
  7. Wang L, et al. 2020. Cells. 0.458333333. PubMed
  8. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  9. Khamissi FZ, et al. 2022. Sci Adv. 8:eabm5900. PubMed
  10. Han H, et al. 2021. Front Pharmacol. 12:726586. PubMed
  11. Park JG, et al. 2021. iScience. 24(9):102941. PubMed
  12. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  13. Brandt S, et al. 2020. J Am Soc Nephrol. 31:2589. PubMed
  14. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  15. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  16. Wang LT, et al. 2021. STAR Protocols. 2(1):100337. PubMed
  17. Angelidis I, et al. 2019. Nat Commun. 10:963. PubMed
  18. Lee RD, et al. 2021. Nat Commun. 12:6843. PubMed
  19. Ma M, et al. 2021. Front Immunol. 12:718779. PubMed
  20. Green DP, et al. 2019. Neuron. 101:412. PubMed
  21. Peres-Emidio EC, et al. 2022. Front Cell Infect Microbiol. 12:811474. PubMed
  22. Dane EL, et al. 2022. Nat Mater. 21:710. PubMed
  23. Lissner MM, et al. 2020. Elife. 9:00. PubMed
  24. Jackson-Jones LH, et al. 2020. Immunity. 52:700. PubMed
  25. Barman PK, et al. 2019. J Immunol. 202:2720. PubMed
  26. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  27. Linehan JL et al. 2018. Cell. 172(4):784-796 . PubMed
  28. Pereira JA, et al. 2020. Hum Mol Genet. 29:1253. PubMed
  29. Baudoux T, et al. 2018. Sci Rep. 4.0375. PubMed
  30. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  31. Ghandhi SA, et al. 2022. Sci Rep. 12:14124. PubMed
  32. Yu Y, et al. 2022. Nat Commun. 13:6857. PubMed
  33. Hassan AO, et al. 2021. Cell Reports. 36(4):109452. PubMed
  34. K?hler D, et al. 2020. Nat Commun. 11:1315. PubMed
  35. Liu T, et al. 2022. Front Immunol. 13:901349. PubMed
  36. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  37. Macdougall CE et al. 2018. Cell metabolism. 27(3):588-601 . PubMed
  38. Zeng Z, et al. 2022. Oncogene. :. PubMed
  39. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  40. Murakami K, et al. 2021. Cell Reports. 34(1):108579. PubMed
  41. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  42. Liyanage S, et al. 2016. Exp Eye Res. 151:160-70. PubMed
  43. Kostadinova E, et al. 2016. Sci Rep. 6:30943. PubMed
  44. Ermert D, et al. 2016. PLoS Pathog. 11: 1005043. PubMed
  45. Pundir P, et al. 2020. Cell Host & Microbe. 26(1):114-122. PubMed
  46. Andrade ACDSP, et al. 2021. J Virol. 95:e0127621. PubMed
  47. Hasegawa T, et al. 2020. Sci Rep. 10:13480. PubMed
  48. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  49. Niderla-Bielinska J, et al. 2021. Int J Mol Sci. :22. PubMed
  50. Wang LT, et al. 2020. Cell Rep. 32:108188. PubMed
  51. Kullberg M, et al. 2015. Nanomedicine. 11: 1355-1363. PubMed
  52. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  53. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  54. Olson B, et al. 2021. Brain Behav Immun. 97:102. PubMed
  55. Alexander Mildner et al. 2017. Immunity. 46(5):849-862 . PubMed
  56. Rustenhoven J, et al. 2021. Cell. 184(4):1000-1016.e27. PubMed
  57. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  58. Gardner P, et al. 2017. Sci Rep. 7:40830. PubMed
  59. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  60. Morein D, et al. 2021. Cells. 10: . PubMed
  61. La Salvia S, et al. 2020. Am J Physiol Renal Physiol. 319:F868. PubMed
  62. Bertuzzi M, et al. 2014. PLoS Pathog. 10:1004413. PubMed
  63. Fransén Pettersson N, et al. 2018. PLoS One. 13:e0203228. PubMed
  64. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  65. Harding CL, et al. 2020. Front Cell Infect Microbiol. 10:328. PubMed
  66. Herbst S, et al. 2015. EMBO Mol Med. 30:240. PubMed
  67. Nepal S, et al. 2019. Proc Natl Acad Sci U S A. 116:16513. PubMed
  68. Zheng C, et al. 2021. J Extracell Vesicles. 10:e12109. PubMed
  69. Li H, et al. 2021. J Clin Invest. 131:. PubMed
  70. Xiong S, et al. 2020. J Clin Invest. 130:3684. PubMed
  71. Lau A, et al. 2022. Sci Adv. 8:eabm0142. PubMed
  72. Kennedy J, et al. 2014. J Exp Med. 211:2519. PubMed
RRID
AB_10897944 (BioLegend Cat. No. 127627) AB_2562567 (BioLegend Cat. No. 127628)

Antigen Details

Structure
A 21-35 kD GPI-anchorded membrane protein
Distribution

Expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes. The monoclonal antibody RB6-8C5 recognizes both Ly-6G and Ly-6C.

Cell Type
Granulocytes, Macrophages, Monocytes
Biology Area
Immunology, Innate Immunity
Antigen References

Fleming TJ, et al. 1993. J. Immunol. 151:2399.

Gene ID
546644 View all products for this Gene ID
UniProt
View information about Ly-6G on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线